MOTS-C (10 mg) & SS-31 (10 mg) (Stack)
MOTS-C (mitochondrial metabolic regulator, AMPK) and SS-31/Elamipretide (cardiolipin protection) complementarily target the mitochondria: MOTS-C improves metabolism/energy expenditure, SS-31 stabilizes the mitochondrial membrane and reduces ROS.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
**MOTS-C** activates AMPK by inhibiting the folate cycle, enhancing glucose uptake, fatty acid oxidation, and mitochondrial respiration. **SS-31** binds to cardiolipin in the inner mitochondrial membrane, stabilizes complexes III/IV, reduces ROS, and improves ATP synthesis. The combination: MOTS-C → metabolic optimization | SS-31 → structural mitochondrial protection.
Quick Start
- MOTS-C: Add 2.0 mL BAC water → 5 mg/mL.
- SS-31: Add 2.0 mL BAC water → 5.0 mg/mL.
- MOTS-C: 5 mg 2–3×/week subcutaneously.
- SS-31: 5–10 mg 1×/day subcutaneously.
- Storage: MOTS-C: 2–8 °C, within 28 days. SS-31: 2–8 °C, within 28 days.
MOTS-C (2–3×/wk) & SS-31 (Daily) Dosing
Route: Subcutaneously | Frequency: MOTS-C: 2–3×/wk | SS-31: 1×/day
| Week | Dose | Units (per injection) |
|---|---|---|
| — MOTS-C — | ||
| Weeks 1–2 | 5 mg | 100 units (1.00 mL) × 2/wk |
| Weeks 3–8 | 5 mg | 100 units (1.00 mL) × 3/wk |
| — SS-31 — | ||
| Weeks 1–2 | 5 mg | 100 units (1.0 mL) |
| Weeks 3–8 | 10 mg | 1 vial |
MOTS-C: 2×/wk in weeks 1–2, then 3×/wk. SS-31: stable dose after 2 weeks. Can be injected on the same day at different sites.
Related compounds
Reconstitution Steps
Dilution Selection
Peptides come in 3 mL, 5 mL or 10 mL vials. If your vial is smaller, the water amount adjusts automatically.
MOTS-C (10 mg)
SS-31 (10 mg)
⚠️ Units change depending on BAC water — always verify before administration. Based on
- MOTS-C: Withdraw 2.0 mL of BAC water → 5 mg/mL.
- SS-31: Withdraw 2.0 mL of BAC water → 5.0 mg/mL.
- Note the date & peptide; refrigerate at 2–8 °C.
Protocol Overview
- Goal: Mitochondrial rejuvenation via a dual mechanism: metabolism (MOTS-C) + structural protection (SS-31).
- Schedule: SS-31 daily, MOTS-C 2–3 times/week, for 8 weeks.
- MOTS-C: 5 mg × 2–3/wk.
- SS-31: 5–10 mg/day.
Dosing Protocol
- MOTS-C: 5 mg × 2/wk (Wks 1–2) → 5 mg × 3/wk (Wks 3–8).
- SS-31: 5 mg/day (wks 1–2) → 10 mg/day (wks 3–8).
- Timing: Both in the morning; at different sites.
- Break between cycles: After the cycle, a break of 4–6 weeks is recommended. Mitochondrial peptides require time to evaluate results and avoid tolerance.
Washout & Cycle Restart
When can I restart?
After the cycle, a break of 4–6 weeks is recommended. Mitochondrial peptides require time to evaluate results and avoid tolerance.
Minimum wait period: 4 weeks
Storage Instructions
- MOTS-C: Lyophilized −20 °C; reconstituted 2–8 °C within 28 days.
- SS-31: Lyophilized −20 °C; reconstituted 2–8 °C within 28 days.
Important Notes
- Can be administered at the same time at different sites.
- SS-31 is in Phase III clinical trials — it is not an approved drug.
Potential Benefits & Side Effects
Potential Benefits:
- MOTS-C: Improved insulin sensitivity, reduction of visceral fat, increased endurance.
- SS-31: Mitochondrial membrane protection, ROS reduction, increased ATP.
- Combination: Holistic mitochondrial support (function + structure).
Potential Side Effects:
- MOTS-C: none reported in preclinical studies.
- SS-31: mild injection site reaction, rare headache.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
AMPK regulation — effect on glucose metabolism
MOTS-c activates AMPK and modifies glucose metabolism. Combined with antidiabetic drugs, may theoretically cause hypoglycemia. Very few human studies.
📄 Cell Metab 2015Renal safety under evaluation
Elamipretide is being evaluated for renal mitochondriopathies. Phase 3 in Barth syndrome did not meet primary endpoint.
📄 Stealth BioTherapeutics — Phase 3 ResultsReferences
- Cell Metabolism (2015) — MOTS-c: metabolic homeostasis via AMPK
View Source - Nature Communications (2021) — MOTS-c regulator of age-dependent physical decline
View Source - Br J Pharmacol (2014) — SS-31: cardiolipin-protective action
View Source - GeroScience (2023) — Elamipretide improves ADP sensitivity in aged mitochondria
View Source
Recommended Supplements
NMN (Nicotinamide Mononucleotide)
CoQ10 (Ubiquinol)
Vitamin E (Mixed Tocopherols)
🧬 General Wellness
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
Elamipretide · Barth syndrome / Mitochondrial disorders (2020)
Barth syndrome (NCT05168774)
FDA Breakthrough Therapy
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →